drugset
drugset / Trial / NCT01554397

Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer

NCT01554397 ↗

Phase 2/3 Completed 101 enrolled University of California, San Diego National Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to find out whether patients with cervical cancer treated with PET-guided Bone Marrow Sparing IMRT have less side effects with equal cancer control compared to standard radiation techniques (IMRT). The hypothesis is that PET-guided Bone Marrow Sparing IMRT will reduce acute hematologic and gastrointestinal toxicity and increase chemotherapy tolerance for cervical cancer patients treated with concurrent cisplatin.

Timeline

Start
2011-10-13
Primary completion
2021-06-01
Completion
2022-01-01

Drugs

EvaluationDrugModalityDoseRoute
Background Cisplatin Other / unclassified 40 mg/m2 —

Indications

cervical cancer